-Charles Erlichman Researcher Activity Profile

Research Author Detailed Information 

Charles Erlichman Publication Rate By Year

Charles Erlichman has published 1 paper(s) in 1981, 5 paper(s) in 2006, 4 paper(s) in 2007, 2 paper(s) in 2008, for a total of 12 research publications in total.

Charles C Erlichman Author Information

LAST NAME: erlichman

FIRST NAME: Charles

INITIALS: c

AFFILIATION:

Papers

Charles Erlichman's Publication Record

1. A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors. Year Published: 2006
Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
2. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Year Published: 2006
Molecular Medicine Program, Mayo Clinic, Rochester, MN, USA.
3. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Year Published: 2006
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA. hhbailey@wisc.edu
4. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Year Published: 2006
Department of Molecular Pharmacology, Mayo Clinic College of Medicine, Mayo Clinic and Foundation, Rochester, Minnesota, USA.
5. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Year Published: 2006
Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
6. Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. Year Published: 2007
Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA. mcwilliams.robert@mayo.edu
7. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Year Published: 2007
Division of Hematology, Rochester, MN, USA. mesa.ruben@mayo.edu
8. A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin. Year Published: 2007
Division of Biostatistics, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
9. A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin. Year Published: 2007
Division of Biostatistics, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
10. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite. Year Published: 1981
11. Medical management of pancreatic neuroendocrine tumors. Year Published: 2008
Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota, USA, and Institut Jules Bordet, Brussels, Belgium.
12. Medical management of pancreatic neuroendocrine tumors. Year Published: 2008
Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.